Analysts’ Weekly Ratings Updates for Definium Therapeutics (DFTX)

A number of firms have modified their ratings and price targets on shares of Definium Therapeutics (NASDAQ: DFTX) recently:

• 8/8/2026 – Definium Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/7/2026 – Definium Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $75.00 price target on the stock, up from $73.00.
• 7/27/2026 – Definium Therapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $68.00 price target on the stock.
• 7/27/2026 – Definium Therapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $68.00 price target on the stock.
• 7/26/2026 – Definium Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/24/2026 – Definium Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $73.00 price target on the stock, up from $48.00.
• 7/18/2026 – Definium Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – Definium Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/8/2026 – Definium Therapeutics had its price target raised by Stifel Nicolaus from $30.00 to $60.00. They now have a “buy” rating on the stock.
• 7/4/2026 – Definium Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/30/2026 – Definium Therapeutics was given a new $58.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 6/24/2026 – Definium Therapeutics had its price target raised by JonesTrading from $61.00 to $74.00. They now have a “buy” rating on the stock.
• 6/23/2026 – Definium Therapeutics had its price target raised by Robert W. Baird from $37.00 to $57.00. They now have an “outperform” rating on the stock.
• 6/23/2026 – Definium Therapeutics had its price target raised by Needham & Company LLC from $38.00 to $50.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Definium Therapeutics had its “buy” rating reaffirmed by Citigroup Inc..
• 6/22/2026 – Definium Therapeutics was given a new $60.00 price target by Canaccord Genuity Group Inc..
• 6/22/2026 – Definium Therapeutics was given a new $60.00 price target by Oppenheimer Holdings, Inc.. They now have an “outperform” rating on the stock.
• 6/22/2026 – Definium Therapeutics had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 6/22/2026 – Definium Therapeutics was given a new $52.00 price target by Leerink Partners. They now have an “outperform” rating on the stock.
• 6/16/2026 – Definium Therapeutics had its “buy” rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $38.00 price target on the stock.

Insiders Place Their Bets

In other news, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the transaction, the chief financial officer owned 209,487 shares in the company, valued at approximately $9,433,199.61. This represents a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert Barrow sold 29,208 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $1,315,236.24. Following the sale, the chief executive officer directly owned 1,098,246 shares in the company, valued at $49,454,017.38. This trade represents a 2.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 48,096 shares of company stock valued at $2,165,763 over the last quarter. Corporate insiders own 2.40% of the company’s stock.

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.